Sohomoy

Boron Neutron Capture Therapy (BNCT) System Market – Targeted Cancer Therapy Gains Momentum

3 min read
0
Comments
157
Views

The boron neutron capture therapy system market focuses on specialized equipment and compounds used in BNCT, a targeted cancer treatment that combines boron-10 delivery agents with neutron irradiation to selectively destroy tumor cells while sparing healthy tissue. BNCT is particularly promising for recurrent, locally advanced, or radioresistant tumors.

The market was valued at around USD 800 million in 2024, about USD 900 million in 2025, and is projected to reach roughly USD 1.8 billion by 2035, growing at a CAGR of approximately 7.1%. Growth is driven by increasing cancer prevalence, rising demand for targeted therapies, advancements in neutron capture technology, supportive regulatory frameworks, and growing R&D investments.

By application, cancer treatment dominates, reflecting BNCT’s primary use in oncology for glioblastoma, head and neck cancers, melanoma, and other solid tumors. Animal studies and radiology represent smaller but growing segments, supporting preclinical research and imaging integration.

Technology segmentation includes boron compounds (enhancing delivery and tumor selectivity), neutron sources (accelerator-based or reactor-based), and detection systems (monitoring therapy efficacy and dosimetry). Advances in each area are improving treatment precision and patient outcomes.

End users include hospitals (largest segment), research institutes, and clinical settings. Hospitals drive adoption through patient volumes and advanced therapeutic offerings. Research institutes innovate BNCT techniques and conduct trials. Clinical settings integrate BNCT into practice, emphasizing safety and outcomes.

North America leads the market, supported by strong healthcare infrastructure, significant R&D in oncology, and increasing patient demand for advanced treatments. Europe follows with growing adoption and collaborative networks. Asia-Pacific is emerging rapidly, with Japan at the forefront of clinical innovation and investment.

Key players include Synchrotron Light Research Institute, Elekta, Accuray Incorporated, Toshiba Medical Systems, Boron Medical, Nordion, PharmaLogic, Proton Medical Systems, GyroJet Medical, and CIVCO Medical Solutions. Recent developments include collaborations to develop BNCT-ready platforms, integrated planning software, and contracts to supply BNCT-enabled systems to leading cancer centers.

Read more: Global Boron Neutron Capture Therapy System Market Research Report

People Also Ask

Q1. What is boron neutron capture therapy (BNCT)?
BNCT is a targeted cancer treatment that combines boron-10 delivery agents with neutron irradiation to selectively destroy tumor cells while minimizing damage to surrounding healthy tissue, offering promise for difficult-to-treat cancers.

Q2. Which application segment is largest in the BNCT system market?
Cancer treatment is the largest application segment, reflecting BNCT’s primary use in oncology for glioblastoma, head and neck cancers, melanoma, and other solid tumors.

Tags: boron neutron capture therapy, BNCT systems, targeted cancer therapy, neutron sources, oncology devices, precision medicine